Nathanael Gray, PhD
Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Dana-Farber Cancer Institute
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome.
Authors: Authors: Rao S, Gurbani D, Du G, Everley RA, Browne CM, Chaikuad A, Tan L, Schröder M, Gondi S, Ficarro SB, Sim T, Kim ND, Berberich MJ, Knapp S, Marto JA, Westover KD, Sorger PK, Gray NS.
Cell Chem Biol
View full abstract on Pubmed
Cell Chem Biol
View full abstract on Pubmed
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Authors: Authors: Brien GL, Remillard D, Shi J, Hemming ML, Chabon J, Wynne K, Dillon ET, Cagney G, Van Mierlo G, Baltissen MP, Vermeulen M, Qi J, Fröhling S, Gray NS, Bradner JE, Vakoc CR, Armstrong SA.
Elife
View full abstract on Pubmed
Elife
View full abstract on Pubmed
Plasticity in binding confers selectivity in ligand-induced protein degradation.
Authors: Authors: Nowak RP, DeAngelo SL, Buckley D, He Z, Donovan KA, An J, Safaee N, Jedrychowski MP, Ponthier CM, Ishoey M, Zhang T, Mancias JD, Gray NS, Bradner JE, Fischer ES.
Nat Chem Biol
View full abstract on Pubmed
Nat Chem Biol
View full abstract on Pubmed
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
Authors: Authors: Zheng Y, Sethi R, Mangala LS, Taylor C, Goldsmith J, Wang M, Masuda K, Karaminejadranjbar M, Mannion D, Miranda F, Herrero-Gonzalez S, Hellner K, Chen F, Alsaadi A, Albukhari A, Fotso DC, Yau C, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Knapp S, Gray NS, Campo L, Myers KA, Dhar S, Ferguson D, Bast RC, Sood AK, von Delft F, Ahmed AA.
Nat Commun
View full abstract on Pubmed
Nat Commun
View full abstract on Pubmed
Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5.
Authors: Authors: Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, Sarhan AR, Hillen A, Velde GV, Gray NS, Alessi DR, Cunningham DL, Tournier C, Johnston SA, May RC.
Sci Adv
View full abstract on Pubmed
Sci Adv
View full abstract on Pubmed
Discovery of a potent dual ALK and EGFR T790M inhibitor.
Authors: Authors: Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS.
Eur J Med Chem
View full abstract on Pubmed
Eur J Med Chem
View full abstract on Pubmed
A benzo[b]thiophene-based selective type 4 S1P receptor agonist.
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Authors: Authors: Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP.
Blood
View full abstract on Pubmed
Blood
View full abstract on Pubmed
The ins and outs of selective kinase inhibitor development.
Authors: Authors: Müller S, Chaikuad A, Gray NS, Knapp S.
Nat Chem Biol
View full abstract on Pubmed
Nat Chem Biol
View full abstract on Pubmed
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Authors: Authors: Ercan D, Choi HG, Yun CH, Capelletti M, Xie T, Eck MJ, Gray NS, Jänne PA.
Clin Cancer Res
View full abstract on Pubmed
Clin Cancer Res
View full abstract on Pubmed